We're downgrading Lilly and asking ourselves tough questions after its obesity pill letdown

Eli Lilly shares plummeted over 14% despite reporting robust second-quarter results, with revenue up 38% and EPS up 61% year-over-year, both exceeding Wall Street expectations, and raising full-year guidance. The significant stock decline was driven by investor disappointment regarding late-stage trial data for its experimental daily oral weight-loss drug, orforglipron, which achieved an average 12.4% body weight reduction but fell short of the Street's higher expectation of approximately 15%, a benchmark set by rival injectable GLP-1s like Wegovy. This perceived efficacy gap has intensified competitive concerns within the lucrative GLP-1 market, leading to analyst downgrades and clouding the company's market leadership narrative.

Analysis

Eli Lilly reported a significant disconnect between its stellar second-quarter financial performance and forward-looking investor sentiment, triggering a severe stock decline of over 14%. The company posted robust results, with revenue jumping 38% year-over-year to $15.56 billion and adjusted EPS surging 61% to $6.31, both comfortably beating Wall Street consensus. Furthermore, Lilly raised its full-year guidance for sales and earnings above analyst expectations, driven by the continued market share gains and strong uptake of its key drugs, Mounjaro and Zepbound. However, this fundamental strength was completely overshadowed by disappointing late-stage trial data for its experimental oral weight-loss pill, orforglipron. While the drug met all of Lilly's pre-set benchmarks, the 12.4% average weight loss achieved fell short of the market's informal expectation of around 15%, a figure benchmarked against rival Novo Nordisk's injectable Wegovy. This perceived efficacy gap has punctured the narrative of Lilly's unquestioned dominance in the GLP-1 space, leading to analyst downgrades and raising concerns about its future competitive positioning, especially as Novo Nordisk may leverage a recent CVS Health deal to compete more aggressively on price.

Key Decisions for Investors

• Investors should re-evaluate long-term growth forecasts for Eli Lilly, as the orforglipron trial results introduce significant uncertainty regarding its competitive positioning and market share potential in the oral obesity drug segment.
• Exercise caution with Lilly's premium valuation, as the sharp negative sentiment shift and analyst downgrades suggest the market is repricing the stock's risk profile following the pipeline setback.
• Closely monitor competitive actions from Novo Nordisk, particularly around pricing, as well as the sustained sales performance of existing blockbusters Mounjaro and Zepbound, which now carry a greater burden to support the company's growth trajectory.